Does the development of new medicinal products in the European Union address global and regional health concerns?
Open Access
- 20 December 2010
- journal article
- Published by Springer Nature in Population Health Metrics
- Vol. 8 (1) , 34
Abstract
Since 1995, approval for many new medicinal products has been obtained through a centralized procedure in the European Union. In recent years, the use of summary measures of population health has become widespread. We investigated whether efforts to develop innovative medicines are focusing on the most relevant conditions from a global public health perspective.Keywords
This publication has 19 references indexed in Scilit:
- Funding of US Biomedical Research, 2003-2008JAMA, 2010
- Relación en España entre la investigación sanitaria financiada por el Sistema Nacional de Salud y la carga de enfermedad en la comunidadRevista Espanola de Salud Publica, 2009
- How can we regulate medicines better?BMJ, 2007
- Regulatory policies on medicines for psychiatric disorders: is Europe on target?The British Journal of Psychiatry, 2007
- Health Burden and Funding at the Centers for Disease Control and PreventionAmerican Journal of Preventive Medicine, 2006
- The Global Burden of Chronic DiseasesJAMA, 2004
- Efficacy, safety and cost of new cardiovascular drugs: a surveyEuropean Journal of Clinical Pharmacology, 2003
- Efficacy, safety, and cost of new anticancer drugsBMJ, 2002
- El medicamento como solución y como problema para la salud pública. Una breve incursión a los objetivos de la farmacoepidemiologíaRevista Espanola de Salud Publica, 2001
- The Relation between Funding by the National Institutes of Health and the Burden of DiseaseNew England Journal of Medicine, 1999